Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Alkermes Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 2 distinct examiners and 2 distinct art units, so the profile reflects separate examination paths.
WHITE, DAWANNA SHAR-DAY is the busiest examiner, with 1 pending matter. The data does not show examiner concentration above 1 action. Practitioners should therefore track each response independently and align arguments with the specific art unit handling the application.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VAJDA, KRISTIN ANN | 1 | 83.8% | +11.1% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.4% | +24.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18983718 | Substituted Fused Bicyclic Compounds and Related Methods of Treatment | VAJDA, KRISTIN ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18983718 | Substituted Fused Bicyclic Compounds and Related Methods of Treatment | VAJDA, KRISTIN ANN | — |
| 18983619 | Substituted Pyrrolidinyl And Piperidinyl Compounds And Related Methods Of Treatment | WHITE, DAWANNA SHAR-DAY | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18983718 | Substituted Fused Bicyclic Compounds and Related Methods of Treatment | VAJDA, KRISTIN ANN | 1622 | §101 | Non-Final OA | — | Pending | Dec 17, 2024 |
| 18983619 | Substituted Pyrrolidinyl And Piperidinyl Compounds And Related Methods Of Treatment | WHITE, DAWANNA SHAR-DAY | 1627 | §102§103DP | Non-Final OA | — | Pending | Dec 17, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAlkermes Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Kristin Ann Vajda has the most, with 1 of Alkermes Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
